FDA approves weekly therapy for adult growth hormone deficiency

FDA approved Sogroya (somapacitan) on August 28 for adults with growth hormone deficiency. Sogroya is the first human growth hormone (hGH) therapy that adult patients only take once a week; other FDA-approved hGH formulations for adults with growth hormone deficiency must be administered daily.

Source: FDA Center for Drug Evaluation and Research - What's New - September 30, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news